OptimizeRx Corporation reported a net revenue of $19.8 million for the first quarter of 2026, a decrease of 10% from $21.9 million in the same period of 2025. The decline was primarily attributed to a reduction in revenue from a low-margin managed service program, which previously accounted for approximately 9.8% of total revenue in 2025. Additionally, the company did not generate revenue from a significant customer that represented about 10% of total revenue in the prior year. Despite these challenges, the company noted increased spending from new and existing customers, which partially offset the revenue decline.

The company's total expenses decreased significantly to $19.4 million from $24.0 million year-over-year, marking a 19% reduction. This decrease was driven by a substantial drop in the cost of revenues, which fell to $4.9 million from $8.6 million, reflecting a shift away from lower-margin services. General and administrative expenses also decreased due to ongoing efficiency initiatives, while sales and marketing expenses remained relatively stable. As a result, OptimizeRx reported an operating income of $396, compared to a loss of $2.1 million in the previous year.

In terms of financial position, OptimizeRx had total assets of $167.3 million as of March 31, 2026, down from $176.9 million at the end of 2025. Current assets were reported at $56.2 million, with current liabilities of $10.5 million, resulting in a working capital of $45.7 million and a current ratio of 5.4. The company’s long-term debt stood at $21.3 million, with a term loan that was recently extended to October 2029. The company also announced a share repurchase program, authorizing the buyback of up to $10 million of its common stock.

Looking ahead, OptimizeRx aims to enhance its revenue growth through a strategic focus on higher-margin solutions and a transition to a subscription-based model for data services. The company is also navigating macroeconomic challenges, including inflation and changes in customer spending patterns, which may impact future performance. Despite these uncertainties, OptimizeRx remains committed to expanding its customer base and improving operational efficiencies to drive profitability.

About OptimizeRx Corp

OptimizeRx Corporation is a healthcare technology company specializing in digital marketing solutions for the life sciences industry. It offers AI-driven audience targeting, omnichannel engagement, and patient and provider communication platforms. Serving pharmaceutical manufacturers and healthcare providers, it enhances brand visibility, patient access, and treatment support through proprietary data, privacy-safe targeting, and integrated digital channels. Its business model focuses on innovative, scalable solutions to improve healthcare marketing and patient outcomes.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.